Download PDF
Semin Thromb Hemost 2012; 38(07): 667-672
DOI: 10.1055/s-0032-1324713
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Approaches to Optimal Dosing of Vitamin K Antagonists

Daniel M. Witt
1   Clinical Pharmacy Research & Applied Pharmacogenomics, Kaiser Permanente Colorado, Aurora, Colorado
› Author Affiliations
Further Information

Publication History

Publication Date:
14 August 2012 (online)

    Permissions and Reprints

Abstract

Although vitamin K antagonists (VKAs) such as warfarin have been used clinically for decades, evidence supporting how best to manage their use in clinical practice is lacking, but continues to emerge. This article summarizes available information regarding the clinical management of VKAs with focus on dosing strategies. For patients with previously stable international normalized ratio (INR) control, the single mildly out-of-range INR does not warrant a change in VKA dose. For out-of-range INRs, prompt repeat testing is associated with better INR control. After the first or second in-range INR value a maximum recall interval of 28 days is optimal, but after the third or greater consecutive in-range INR, longer recall intervals (up to 12 weeks for very stable patients) can be used. The use of validated VKA dosing nomograms is suggested as a means of reducing unwanted variability in VKA dosing decisions. Ensuring timely INR monitoring, and adjusting VKA doses when necessary, is important when interacting medications are prescribed during VKA therapy. Daily low-dose vitamin K supplementation is unlikely to improve INR control in patients with stable INR control but may be of benefit in VKA patients with unexplainable variability in the INR response. Dosing decisions during VKA therapy should follow a systematic and coordinated process as used in dedicated anticoagulation management services. Patient self-management of VKA therapy offers advantages for motivated patients who can demonstrate competency in self-management including fingerstick INR testing. Most patients with excessive anticoagulation who are not bleeding can be managed without administering vitamin K. There is an ongoing need for research evaluating VKA dosing practices that can consistently improve the outcomes of VKA therapy.

Keywords

vitamin K antagonists - warfarin - anticoagulation - international normalized ratio
 

  • References

  • 1 Holbrook A, Schulman S, Witt DM , et al; American College of Chest Physicians. Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141: e152S-e184S
    CrossrefPubMedGoogle Scholar
  • 2 Rose AJ, Ozonoff A, Berlowitz DR, Henault LE, Hylek EM. Warfarin dose management affects INR control. J Thromb Haemost 2009; 7 (1) 94-101
    CrossrefPubMedGoogle Scholar
  • 3 Schulman S, Melinyshyn A, Ennis D, Rudd-Scott L. Single-dose adjustment versus no adjustment of warfarin in stably anticoagulated patients with an occasional international normalized ratio (INR) out of range. Thromb Res 2010; 125 (5) 393-397
    CrossrefPubMedGoogle Scholar
  • 4 Banet GA, Waterman AD, Milligan PE, Gatchel SK, Gage BF. Warfarin dose reduction vs watchful waiting for mild elevations in the international normalized ratio. Chest 2003; 123 (2) 499-503
    CrossrefPubMedGoogle Scholar
  • 5 Fihn SD, McDonell MB, Vermes D , et al; National Consortium of Anticoagulation Clinics. A computerized intervention to improve timing of outpatient follow-up: a multicenter randomized trial in patients treated with warfarin. J Gen Intern Med 1994; 9 (3) 131-139
    CrossrefPubMedGoogle Scholar
  • 6 Ansell J, Hirsh J, Hylek E , et al; American College of Chest Physicians. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133: 160S-198S
    CrossrefPubMedGoogle Scholar
  • 7 Heneghan C, Ward A, Perera R , et al; Self-Monitoring Trialist Collaboration. Self-monitoring of oral anticoagulation: systematic review and meta-analysis of individual patient data. Lancet 2012; 379 (9813) 322-334
    CrossrefPubMedGoogle Scholar
  • 8 Matchar DB, Jacobson A, Dolor R , et al; THINRS Executive Committee and Site Investigators. Effect of home testing of international normalized ratio on clinical events. N Engl J Med 2010; 363 (17) 1608-1620
    CrossrefPubMedGoogle Scholar
  • 9 Rose AJ, Hylek EM, Berlowitz DR, Ash AS, Reisman JI, Ozonoff A. Prompt repeat testing after out-of-range INR values: a quality indicator for anticoagulation care. Circ Cardiovasc Qual Outcomes 2011; 4 (3) 276-282
    CrossrefPubMedGoogle Scholar
  • 10 Rose AJ, Ozonoff A, Berlowitz DR, Ash AS, Reisman JI, Hylek EM. Reexamining the recommended follow-up interval after obtaining an in-range international normalized ratio value: results from the Veterans Affairs study to improve anticoagulation. Chest 2011; 140 (2) 359-365
    CrossrefPubMedGoogle Scholar
  • 11 Lidstone V, Janes S, Stross P. INR: intervals of measurement can safely extend to 14 weeks. Clin Lab Haematol 2000; 22 (5) 291-293
    CrossrefPubMedGoogle Scholar
  • 12 Pengo V, Barbero F, Biasiolo A, Pegoraro C, Cucchini U, Iliceto S. A comparison between six- and four-week intervals in surveillance of oral anticoagulant treatment. Am J Clin Pathol 2003; 120 (6) 944-947
    CrossrefPubMedGoogle Scholar
  • 13 Rose AJ, Ozonoff A, Henault LE, Hylek EM. Warfarin for atrial fibrillation in community-based practise. J Thromb Haemost 2008; 6 (10) 1647-1654
    CrossrefPubMedGoogle Scholar
  • 14 Schulman S, Parpia S, Stewart C, Rudd-Scott L, Julian JA, Levine M. Warfarin dose assessment every 4 weeks versus every 12 weeks in patients with stable international normalized ratios: a randomized trial. Ann Intern Med 2011; 155 (10) 653-659 , W201–3
    CrossrefPubMedGoogle Scholar
  • 15 Witt DM, Delate T, Clark NP , et al; Warfarin Associated Research Projects and other EnDeavors (WARPED) Consortium. Outcomes and predictors of very stable INR control during chronic anticoagulation therapy. Blood 2009; 114 (5) 952-956
    CrossrefPubMedGoogle Scholar
  • 16 Witt DM, Delate T, Clark NP , et al; Warped Consortium. Twelve-month outcomes and predictors of very stable INR control in prevalent warfarin users. J Thromb Haemost 2010; 8 (4) 744-749
    CrossrefPubMedGoogle Scholar
  • 17 Ageno W, Turpie AG. A randomized comparison of a computer-based dosing program with a manual system to monitor oral anticoagulant therapy. Thromb Res 1998; 91 (5) 237-240
    CrossrefPubMedGoogle Scholar
  • 18 Manotti C, Moia M, Palareti G, Pengo V, Ria L, Dettori AG. Effect of computer-aided management on the quality of treatment in anticoagulated patients: a prospective, randomized, multicenter trial of APROAT (Automated PRogram for Oral Anticoagulant Treatment). Haematologica 2001; 86 (10) 1060-1070
    PubMedGoogle Scholar
  • 19 Marco F, Sedano C, Bermúdez A, López-Duarte M, Fernández-Fontecha E, Zubizarreta A. A prospective controlled study of a computer-assisted acenocoumarol dosage program. Pathophysiol Haemost Thromb 2003; 33 (2) 59-63
    PubMedGoogle Scholar
  • 20 Mitra R, Marciello MA, Brain C, Ahangar B, Burke DT. Efficacy of computer-aided dosing of warfarin among patients in a rehabilitation hospital. Am J Phys Med Rehabil 2005; 84 (6) 423-427
    CrossrefPubMedGoogle Scholar
  • 21 Poller L, Shiach CR, MacCallum PK , et al. Multicentre randomised study of computerised anticoagulant dosage. European Concerted Action on Anticoagulation. Lancet 1998; 352 (9139) 1505-1509
    CrossrefPubMedGoogle Scholar
  • 22 Poller L, Keown M, Ibrahim S , et al. An international multicenter randomized study of computer-assisted oral anticoagulant dosage vs. medical staff dosage. J Thromb Haemost 2008; 6 (6) 935-943
    CrossrefPubMedGoogle Scholar
  • 23 Vadher BD, Patterson DL, Leaning M. Comparison of oral anticoagulant control by a nurse-practitioner using a computer decision-support system with that by clinicians. Clin Lab Haematol 1997; 19 (3) 203-207
    CrossrefPubMedGoogle Scholar
  • 24 Nieuwlaat R, Barker L, Kim YK , et al. Underuse of evidence-based warfarin dosing methods for atrial fibrillation patients. Thromb Res 2010; 125 (4) e128-e131
    CrossrefPubMedGoogle Scholar
  • 25 Holbrook AM, Pereira JA, Labiris R , et al. Systematic overview of warfarin and its drug and food interactions. Arch Intern Med 2005; 165 (10) 1095-1106
    CrossrefPubMedGoogle Scholar
  • 26 Ahmed A, Stephens JC, Kaus CA, Fay WP. Impact of preemptive warfarin dose reduction on anticoagulation after initiation of trimethoprim-sulfamethoxazole or levofloxacin. J Thromb Thrombolysis 2008; 26 (1) 44-48
    CrossrefPubMedGoogle Scholar
  • 27 Baglin T. Avoiding overanticoagulation: knowing your antibiotics. Thromb Haemost 2002; 88 (5) 703-704
    PubMedGoogle Scholar
  • 28 Dowd MB, Vavra KA, Witt DM, Delate T, Martinez K. Empiric warfarin dose adjustment with prednisone therapy. A randomized, controlled trial. J Thromb Thrombolysis 2011; 31 (4) 472-477
    CrossrefPubMedGoogle Scholar
  • 29 Dowd MB, Kippes KA, Witt DM, Delate T, Martinez K. A randomized controlled trial of empiric warfarin dose reduction with the initiation of doxycycline therapy. Thromb Res 2012; 130: 152-154
    CrossrefPubMedGoogle Scholar
  • 30 Kim KH, Choi WS, Lee JH, Lee H, Yang DH, Chae SC. Relationship between dietary vitamin K intake and the stability of anticoagulation effect in patients taking long-term warfarin. Thromb Haemost 2010; 104 (4) 755-759
    Article in Thieme ConnectPubMedGoogle Scholar
  • 31 Rombouts EK, Rosendaal FR, Van Der Meer FJ. Daily vitamin K supplementation improves anticoagulant stability. J Thromb Haemost 2007; 5 (10) 2043-2048
    CrossrefPubMedGoogle Scholar
  • 32 Sconce E, Avery P, Wynne H, Kamali F. Vitamin K supplementation can improve stability of anticoagulation for patients with unexplained variability in response to warfarin. Blood 2007; 109 (6) 2419-2423
    CrossrefPubMedGoogle Scholar
  • 33 Gebuis EP, Rosendaal FR, van Meegen E, van der Meer FJ. Vitamin K1 supplementation to improve the stability of anticoagulation therapy with vitamin K antagonists: a dose-finding study. Haematologica 2011; 96 (4) 583-589
    CrossrefPubMedGoogle Scholar
  • 34 van Walraven C, Jennings A, Oake N, Fergusson D, Forster AJ. Effect of study setting on anticoagulation control: a systematic review and metaregression. Chest 2006; 129 (5) 1155-1166
    CrossrefPubMedGoogle Scholar
  • 35 Chan FW, Wong RS, Lau WH, Chan TY, Cheng G, You JH. Management of Chinese patients on warfarin therapy in two models of anticoagulation service - a prospective randomized trial. Br J Clin Pharmacol 2006; 62 (5) 601-609
    CrossrefPubMedGoogle Scholar
  • 36 Wilt VM, Gums JG, Ahmed OI, Moore LM. Outcome analysis of a pharmacist-managed anticoagulation service. Pharmacotherapy 1995; 15 (6) 732-739
    PubMedGoogle Scholar
  • 37 Lalonde L, Martineau J, Blais N , et al. Is long-term pharmacist-managed anticoagulation service efficient? A pragmatic randomized controlled trial. Am Heart J 2008; 156 (1) 148-154
    CrossrefPubMedGoogle Scholar
  • 38 Wilson SJ, Wells PS, Kovacs MJ , et al. Comparing the quality of oral anticoagulant management by anticoagulation clinics and by family physicians: a randomized controlled trial. CMAJ 2003; 169 (4) 293-298
    PubMedGoogle Scholar
  • 39 Garcia-Alamino JM, Ward AM, Alonso-Coello P , et al. Self-monitoring and self-management of oral anticoagulation. Cochrane Database Syst Rev 2010; 4 (4) CD003839
    PubMedGoogle Scholar
  • 40 Bloomfield HE, Krause A, Greer N , et al. Meta-analysis: effect of patient self-testing and self-management of long-term anticoagulation on major clinical outcomes. Ann Intern Med 2011; 154 (7) 472-482
    CrossrefPubMedGoogle Scholar
  • 41 Connock M, Stevens C, Fry-Smith A , et al. Clinical effectiveness and cost-effectiveness of different models of managing long-term oral anticoagulation therapy: a systematic review and economic modelling. Health Technol Assess 2007; 11 (38) iii-iv , ix–66
    PubMedGoogle Scholar
  • 42 Heneghan C, Alonso-Coello P, Garcia-Alamino JM, Perera R, Meats E, Glasziou P. Self-monitoring of oral anticoagulation: a systematic review and meta-analysis. Lancet 2006; 367 (9508) 404-411
    CrossrefPubMedGoogle Scholar
  • 43 McCahon D, Murray ET, Jowett S , et al. Patient self-management of oral anticoagulation in routine care in the UK. J Clin Pathol 2007; 60 (11) 1263-1267
    CrossrefPubMedGoogle Scholar
  • 44 Brown A, Wells P, Jaffey J , et al. Point-of-care monitoring devices for long-term oral anticoagulation therapy: clinical and cost effectiveness [Technology report no 72]. Ottawa: Canadian Agency for Drugs and Technologies in Health; 2007
    Google Scholar
  • 45 Jowett S, Bryan S, Murray E , et al. Patient self-management of anticoagulation therapy: a trial-based cost-effectiveness analysis. Br J Haematol 2006; 134 (6) 632-639
    CrossrefPubMedGoogle Scholar
  • 46 Crowther MA, Julian J, McCarty D , et al. Treatment of warfarin-associated coagulopathy with oral vitamin K: a randomised controlled trial. Lancet 2000; 356 (9241) 1551-1553
    CrossrefPubMedGoogle Scholar
  • 47 Crowther MA, Ageno W, Garcia D , et al. Oral vitamin K versus placebo to correct excessive anticoagulation in patients receiving warfarin: a randomized trial. Ann Intern Med 2009; 150 (5) 293-300
    CrossrefPubMedGoogle Scholar
  • 48 Patel RJ, Witt DM, Saseen JJ, Tillman DJ, Wilkinson DS. Randomized, placebo-controlled trial of oral phytonadione for excessive anticoagulation. Pharmacotherapy 2000; 20 (10) 1159-1166
    CrossrefPubMedGoogle Scholar
  • 49 Guyatt GH, Norris SL, Schulman S , et al; American College of Chest Physicians. Methodology for the development of antithrombotic therapy and prevention of thrombosis guidelines: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141: 53S-70S
    CrossrefPubMedGoogle Scholar
  • 50 Wallentin L, Yusuf S, Ezekowitz MD , et al; RE-LY investigators. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet 2010; 376 (9745) 975-983
    CrossrefPubMedGoogle Scholar